2. Autophagy
  3. p62 Mitophagy
  4. ATB1071

ATB1071 is a brain-penetrant and orally active p62/SQSTM1 activator. ATB1071 binds to the p62-ZZ domain, promotes PB1-dependent p62 self-polymerization, and activates p62-mediated mitophagy. ATB1071 can be used for the research of Leigh syndrome, cerebral ischemia-reperfusion injury[1].

For research use only. We do not sell to patients.

ATB1071

ATB1071 Chemical Structure

CAS No. : 2921556-65-0

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

ATB1071 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

ATB1071 is a brain-penetrant and orally active p62/SQSTM1 activator. ATB1071 binds to the p62-ZZ domain, promotes PB1-dependent p62 self-polymerization, and activates p62-mediated mitophagy. ATB1071 can be used for the research of Leigh syndrome, cerebral ischemia-reperfusion injury[1].

In Vitro

ATB1071 (1 mM; 2 h) engages the p62-ZZ domain to promote PB1-dependent p62 oligomerization in HeLa cell lysates[1].
ATB1071 activates p62-dependent selective autophagy in SH-SY5Y cells without engaging canonical AMPK activation or mTOR inhibition[1].
ATB1071 (2.5-10 μM) induces p62-dependent, autophagy-lysosome-mediated clearance of damaged mitochondria selectively under mitochondrial stress in SH-SY5Y cells, with dose-dependent activity at 2.5-10 μM[1].
ATB1071 induces mitophagy in mt-mKeima HeLa cells via a Parkin-independent pathway under Rotenone (HY-B1756)-induced stress, and enhances Parkin-mediated mitophagy under CCCP (HY-100941)-induced stress[1].
ATB1071 activates mitophagy and restores mitochondrial bioenergetic function in NDUFS4-knockdown SH-SY5Y cells, reversing MMP depolarization, ROS elevation, and ATP deficiency[1].
ATB1071 (2-5 μM; 8-24 h) enhances the interaction between p62 and NIPSNAP1 in HEK293T cells, particularly under mitochondrial stress, via a mechanism dependent on the p62 ZZ/PB1 axis[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ATB1071 Related Antibodies
Parmacokinetics
Species Dose Route AUClast T1/2 Bioavailability Brain-to-Plasma Ratio
Mice[1] 10 mg/kg p.o. 5750.6 ng·h/mL 9.8 h 70.4 % 2.12 %
In Vivo

ATB1071 (10 mg/kg; i.p.; every other day; 40 days) activates p62-associated mitophagy in the brain, reduces neuroinflammation, and improves neuromuscular function and survival in a mouse model of Leigh syndrome[1].
ATB1071 (10 mg/kg; i.p.; at 0, 3, 24, and 48 hours post-MCAO) provides robust neuroprotection and restores neurological function after cerebral ischemia-reperfusion injury primarily via EBP1-dependent mitophagy[1].
ATB1071 (10 mg/kg; i.p.; at 0, 3, 24, and 48 hours post-MCAO) has its mediated mitophagy restored by reintroduction of EBP1, which enhances neuroprotection and functional recovery after cerebral ischemia-reperfusion injury in Ebp1-deficient mice[1].
ATB1071 (p.o.; daily for 1 week or 3 times per week for 2 weeks) exhibits NOAEL of at least 30 mg/kg and 300 mg/kg in ICR mice and rats, respectively[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: B6.129S4-Ndufs4m1.1Rpa/J mice (Ndufs4-/-; starting at postnatal day 10); wild-type/heterozygous control mice (starting at postnatal day 10)[1]
Dosage: 10 mg/kg
Administration: i.p.; every other day; 40 days
Result: Increased TOM20+LC3+ proximity ligation assay puncta in the deep cerebellar nuclei and olfactory bulb of Ndufs4-/- mice.
Elevated p62 levels by ~1.8-fold and its oligomeric/aggregated species by ~2.4-fold in the brain mitochondrial fraction.
Reduced GFAP+ astrocytes and Iba1+ microglia.
Lowered expression of inflammation-associated genes (Cd14, Il-1β, S100a8).
Extended median survival by ~31% and maximal lifespan by ~64% relative to vehicle-treated Ndufs4-/- mice.
Improved forelimb grip strength by ~34% at postnatal day 40.
Increased rotarod latency to fall by ~3-fold at postnatal day 50.
Delayed the onset of clasping/twisting by ~12%.
Reduced skin inflammation-associated hair loss severity scores from 2 to 1.22 at postnatal day 20.
Animal Model: Pa2g4flox/flox mice (control; aged 6-8 weeks); CamK2-Cre;Pa2g4flox/flox mice (neuron-specific Ebp1 knockout, Ebp1 CKO; aged 6-8 weeks)[1]
Dosage: 10 mg/kg
Administration: i.p.; at 0, 3, 24, and 48 hours post-MCAO
Result: Decreased TOM20 levels, increased p62 and LC3-II levels, and enhanced recruitment of LC3+ phagophores to TOM20+ mitochondria in the hippocampus of control MCAO mice.
Reduced infarct volume by ~85% in control MCAO mice.
Lowered neuronal death in the CA1 region by ~91% in control MCAO mice.
Increased rotarod latency to fall from 54.7 to 207.4 seconds in control MCAO mice.
Enhanced four-limb grip strength by ~1.3-fold and forelimb grip strength by ~1.6-fold in control MCAO mice.
Increased total open-field travel distance from 1919 to 2579 cm in control MCAO mice.
Raised Y-maze spontaneous alternation rate from 53% to 83% in control MCAO mice.
Blunted effects in Ebp1 CKO mice, with only ~46% infarct volume reduction, ~40% neuronal death reduction, and no significant improvements in motor, behavioral, or cognitive functions.
Animal Model: CamK2-Cre;Pa2g4flox/flox mice (neuron-specific Ebp1 knockout, Ebp1 CKO; aged 6-8 weeks)[1]
Dosage: 10 mg/kg
Administration: i.p.; at 0, 3, 24, and 48 hours post-MCAO
Result: Restored ATB1071-induced mitophagy in Ebp1 CKO mice via EBP1 reintroduction, as shown by increased LC3 and p62 levels and enhanced mitochondrial localization of LC3 in the hippocampus.
Reduced infarct volume by ~67% (vs ~52% in mock-expressing mice).
Lowered neuronal death by ~86% relative to the mock group.
Improved rotarod performance by ~2.2-fold.
Increased four-limb grip strength by ~1.5-fold and forelimb grip strength by ~1.5-fold.
Increased ambulatory activity by ~1.5-fold.
Improved working memory by ~33% compared with mock-expressing Ebp1 CKO mice.
Molecular Weight

443.48

Formula

C25H27F2NO4
CAS No.
SMILES

OCCNCCCOC1=CC(OCC2=CC=C(F)C=C2)=C(OCC3=CC=C(F)C=C3)C=C1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

ATB1071 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

ATB10712921556-65-0ATB 1071ATB-1071p62MitophagySequestosome-1SQSTM1Mitochondrial Autophagyp62/SQSTM1cerebral ischemia-reperfusion injuryNIPSNAP1HeLa cellsp62-ZZ domainmitophagyNIPSNAP2EBP1/PA2G4Leigh syndromePB1Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
ATB1071
Cat. No.:
HY-184089
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.